Glaukos Corp (GKOS)

$84.09 -2.53 (-2.92%)
Market Cap 4.97B
Revenue (ttm) 383.48M
Net Income (ttm) -146.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.17%
Debt to Equity Ratio 0.00
Volume 465,100
Avg Vol 958,834
Day's Range N/A - N/A
Shares Out 57.35M
Stochastic %K 74%
Beta 0.76
Analysts Strong Sell
Price Target $120.64

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
anachartanalyst
anachartanalyst Oct. 7 at 6:02 PM
$GKOS https://anachart.com/wp-content/uploads/ana_temp/1759860148_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 7 at 5:05 PM
Citigroup has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 140 → 110.
0 · Reply
manojaggarwal
manojaggarwal Oct. 5 at 9:30 PM
$GKOS looks interesting; watching
0 · Reply
ninergizer
ninergizer Oct. 3 at 1:20 PM
$GKOS might be a great three weeks. I’ll start a position here. Do your DD. PDUFA set for Oct 20, 2025. Two Phase 3 pivotal trials hit primary Kmax endpoint with ~1.0 D treatment effect (p<0.0001), no ocular SAEs, and discontinuations due to AEs 0% in the treated arm; generally mild, transient AEs. Glaukos has devices approved, but no prior drugs.
0 · Reply
Kingofstocks0001
Kingofstocks0001 Oct. 1 at 9:09 PM
$GKOS going to $195 easy
0 · Reply
FrugalMcLovin
FrugalMcLovin Sep. 26 at 2:31 PM
$GKOS Opened a position here. It’s lost 13.6% in the past month but I expect it to return to that level as it gets closer to PDUFA day on Oct. 20th. When it gets back to that level, I’ll sell most of my position for profits and leave some shares in play for the possible FDA approval.
1 · Reply
JudyTaylor330
JudyTaylor330 Sep. 21 at 4:43 PM
$GKOS Medical device innovation. Breaking above resistance. Volume expansion noted. Relative strength.
0 · Reply
TrendSnatch
TrendSnatch Sep. 15 at 9:32 AM
$GKOS Competitive space; differentiation and margin improvement matter
0 · Reply
JarvisFlow
JarvisFlow Sep. 10 at 11:00 AM
BTIG has updated their rating for Glaukos ( $GKOS ) to Buy with a price target of 118.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 11:28 AM
$GKOS Outstanding article that hits the mark on GKOS's current state. So if you want to refresh your GKOS insights or learn about GKOS from scratch, this is a must read. https://beyondspx.com/quote/GKOS/analysis/glaukos-pioneering-interventional-glaucoma-amidst-market-headwinds-gkos
0 · Reply
Latest News on GKOS
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Sep 25, 2025, 4:05 PM EDT - 12 days ago

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Aug 13, 2025, 7:00 AM EDT - 2 months ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:15 AM EDT - 2 months ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Glaukos Announces Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 2 months ago

Glaukos Announces Second Quarter 2025 Financial Results

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Jul 9, 2025, 7:00 AM EDT - 3 months ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Jun 25, 2025, 4:05 PM EDT - 3 months ago

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Jun 25, 2025, 7:00 AM EDT - 3 months ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Glaukos Announces Participation in Upcoming Investor Conferences

May 13, 2025, 7:00 AM EDT - 5 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:05 PM EDT - 5 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 5 months ago

Glaukos Announces First Quarter 2025 Financial Results

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 5 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR INSM ISRG LLY RDNT

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 6 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 6 months ago

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Apr 9, 2025, 7:00 AM EDT - 6 months ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Mar 11, 2025, 7:00 AM EDT - 7 months ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Feb 24, 2025, 9:12 AM EST - 8 months ago

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 8 months ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Feb 21, 2025, 10:27 AM EST - 8 months ago

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 4:29 AM EST - 8 months ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 4:05 PM EST - 8 months ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 23, 2025, 7:00 AM EST - 9 months ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Jan 14, 2025, 4:05 PM EST - 9 months ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Dec 31, 2024, 8:59 AM EST - 10 months ago

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 10 months ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 21, 2024, 7:04 AM EST - 10 months ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 17, 2024, 7:00 AM EST - 10 months ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Dec 2, 2024, 2:29 PM EST - 11 months ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

ISRG NVRO SYK

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Nov 5, 2024, 12:21 PM EST - 1 year ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:03 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Sep 23, 2024, 1:30 AM EDT - 1 year ago

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:57 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Glaukos Announces Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Second Quarter 2024 Financial Results

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Jul 10, 2024, 9:05 AM EDT - 1 year ago

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

V HELE LZ SPOT

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Jul 10, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

May 1, 2024, 8:42 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

Glaukos Announces First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2024 Financial Results

Glaukos Announces the Release of its 2023 Sustainability Report

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces the Release of its 2023 Sustainability Report

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 11:13 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Jan 31, 2024, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Jan 9, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Alger's Amy Zhang gives her top small-cap stock picks for 2024

Jan 5, 2024, 7:31 AM EST - 1 year ago

Alger's Amy Zhang gives her top small-cap stock picks for 2024

NTRA

anachartanalyst
anachartanalyst Oct. 7 at 6:02 PM
$GKOS https://anachart.com/wp-content/uploads/ana_temp/1759860148_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 7 at 5:05 PM
Citigroup has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 140 → 110.
0 · Reply
manojaggarwal
manojaggarwal Oct. 5 at 9:30 PM
$GKOS looks interesting; watching
0 · Reply
ninergizer
ninergizer Oct. 3 at 1:20 PM
$GKOS might be a great three weeks. I’ll start a position here. Do your DD. PDUFA set for Oct 20, 2025. Two Phase 3 pivotal trials hit primary Kmax endpoint with ~1.0 D treatment effect (p<0.0001), no ocular SAEs, and discontinuations due to AEs 0% in the treated arm; generally mild, transient AEs. Glaukos has devices approved, but no prior drugs.
0 · Reply
Kingofstocks0001
Kingofstocks0001 Oct. 1 at 9:09 PM
$GKOS going to $195 easy
0 · Reply
FrugalMcLovin
FrugalMcLovin Sep. 26 at 2:31 PM
$GKOS Opened a position here. It’s lost 13.6% in the past month but I expect it to return to that level as it gets closer to PDUFA day on Oct. 20th. When it gets back to that level, I’ll sell most of my position for profits and leave some shares in play for the possible FDA approval.
1 · Reply
JudyTaylor330
JudyTaylor330 Sep. 21 at 4:43 PM
$GKOS Medical device innovation. Breaking above resistance. Volume expansion noted. Relative strength.
0 · Reply
TrendSnatch
TrendSnatch Sep. 15 at 9:32 AM
$GKOS Competitive space; differentiation and margin improvement matter
0 · Reply
JarvisFlow
JarvisFlow Sep. 10 at 11:00 AM
BTIG has updated their rating for Glaukos ( $GKOS ) to Buy with a price target of 118.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 11:28 AM
$GKOS Outstanding article that hits the mark on GKOS's current state. So if you want to refresh your GKOS insights or learn about GKOS from scratch, this is a must read. https://beyondspx.com/quote/GKOS/analysis/glaukos-pioneering-interventional-glaucoma-amidst-market-headwinds-gkos
0 · Reply
erkdg
erkdg Sep. 2 at 5:20 PM
$GKOS are we still expecting FDA approval within next 6 weeks? I couldnt find info whether its on track or postponed.
2 · Reply
ZacksResearch
ZacksResearch Sep. 2 at 2:22 PM
$GKOS: Record-breaking first-half 2025 revenue growth, but hurdles remain! 🚀 Glaukos posted a 27.3% YoY revenue increase, fueled by the iDose TR implant's success. However, reimbursement complexities and execution risks could impact near-term momentum ⚠️. See what challenges and opportunities lie ahead for GKOS 👉 https://www.zacks.com/stock/news/2746029/glaukos-builds-dual-growth-engines-amid-market-headwinds?cid=sm-stocktwits-2-2746029-body-10439&ADID=SYND_STOCKTWITS_TWEET_2_2746029_BODY_10439
0 · Reply
ZacksResearch
ZacksResearch Sep. 2 at 1:22 PM
$GKOS just raised revenue guidance 🚀 Record 1H sales driven by iDose TR adoption + strong international glaucoma growth are powering dual engines even with market headwinds. Full breakdown here 👉 https://www.zacks.com/stock/news/2746029/glaukos-builds-dual-growth-engines-amid-market-headwinds?cid=sm-stocktwits-2-2746029-teaser-10438&ADID=SYND_STOCKTWITS_TWEET_2_2746029_TEASER_10438
0 · Reply
CandleRise
CandleRise Aug. 27 at 6:31 AM
$GKOS momentum slowing down, needs strength to push higher.
1 · Reply
Kingofstocks0001
Kingofstocks0001 Aug. 20 at 4:47 AM
$GKOS This will double in 1 year snd triple in 2 years
0 · Reply
bvr91
bvr91 Aug. 14 at 9:08 PM
$GKOS Started my position here at 86.01. So far so good 🤞
0 · Reply
Kingofstocks0001
Kingofstocks0001 Aug. 14 at 7:10 PM
$GKOS to the moon
0 · Reply
TaoistTrader
TaoistTrader Aug. 9 at 7:09 PM
$GKOS Interested in building a position here ...
0 · Reply
d_risk
d_risk Aug. 4 at 10:58 PM
$GKOS - Glaukos Corporation Common Stock - 10Q - Updated Risk Factors GKOS risk factors in 2025 show expanded detail on sales volatility from Medicare changes, orphan drug competition, international regulatory and geopolitical risks, heightened legal and cybersecurity threats including AI, new debt-related risks, refined trade and reimbursement challenges, plus added anti-takeover and exclusive forum provisions; several outdated risks removed, but core themes remain. #MedicareChanges #Anti-TakeoverProvisions #ReimbursementChallenges #TradeChallenges #DebtRisks #AIRisks #LegalAndCybersecurityThreats #GeopoliticalRisks #InternationalRegulatoryRisks #OrphanDrugCompetition 🟢 Added 🟠 Removed https://d-risk.ai/GKOS/10-Q/2025-08-04
1 · Reply
FractionalShareWhale
FractionalShareWhale Jul. 31 at 8:50 PM
$GKOS 🔥👐🏽🔥
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 6:33 PM
Glaukos sheds 2.2% after Q2 results — but is there a silver lining? 💡 📈 Revenue up 29.7% YoY on a reported basis, beating estimates by 8.1% 💰 Raised 2025 sales guidance; promising pipeline progress continues 📉 Headwinds persist from policy-related pressures See what makes $GKOS a potential buy 👉 https://www.zacks.com/stock/news/2644985/gkos-stock-falls-despite-q2-earnings-revenues-beat-guidance-raised?cid=sm-stocktwits-2-2644985-body-5262&ADID=SYND_STOCKTWITS_TWEET_2_2644985_BODY_5262
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 4:56 PM
$GKOS beat Q2 earnings and raised guidance — so why is the stock dropping? Revenue surged, but the ongoing operating loss is still dragging sentiment. Full breakdown here 👉 https://www.zacks.com/stock/news/2644985/gkos-stock-falls-despite-q2-earnings-revenues-beat-guidance-raised?cid=sm-stocktwits-2-2644985-teaser-5184&ADID=SYND_STOCKTWITS_TWEET_2_2644985_TEASER_5184
0 · Reply